BSW Wealth Partners Purchases 188 Shares of Boston Scientific Corporation $BSX

BSW Wealth Partners lifted its position in shares of Boston Scientific Corporation (NYSE:BSX) by 2.2% during the 2nd quarter, Holdings Channel reports. The firm owned 8,667 shares of the medical equipment provider’s stock after purchasing an additional 188 shares during the quarter. BSW Wealth Partners’ holdings in Boston Scientific were worth $931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. 1248 Management LLC bought a new stake in Boston Scientific in the first quarter valued at approximately $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the 1st quarter valued at $27,000. Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific during the 2nd quarter valued at $37,000. Finally, Activest Wealth Management boosted its position in Boston Scientific by 6,216.7% during the first quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 373 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares in the company, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 174,214 shares of company stock valued at $17,972,457. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

Shares of NYSE:BSX opened at $95.78 on Thursday. The business’s 50 day simple moving average is $103.30 and its 200 day simple moving average is $102.08. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $141.91 billion, a P/E ratio of 57.01, a P/E/G ratio of 2.35 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company’s revenue was up 22.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of a number of research reports. Barclays raised their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the stock an “overweight” rating in a research note on Thursday, July 24th. Truist Financial raised their price objective on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday. Canaccord Genuity Group boosted their price objective on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. UBS Group increased their target price on Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, July 24th. Finally, BTIG Research lifted their price target on Boston Scientific from $127.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $120.67.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.